Regeneron Pharmaceuticals Inc
Market cap $93.6B
$904.35
REGN
$904.35
+0.16% today
Buy with €1M virtual cash · No real money
Regeneron Pharmaceuticals Inc (REGN) is a publicly traded company listed on the XNAS. As of November 8, 2026, Invest's signal rates REGN a Buy, with the stock up 40% over the past year. You can practice trading REGN risk-free with €1,000,000 in virtual cash.
Key stats
As of November 8, 2026
Market Cap
$93.6B
Volume
1.1M
52-wk High
$991.73
52-wk Low
$591.52
Day High
$911.64
Day Low
$887.04
Performance
1M
+22.3%
6M
+26.5%
1Y
+40.4%
Invest signal · REGN
BuyAlgorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.
REGN overview
AI overviewLatest REGN news
Why Regeneron (REGN) Might be Well Poised for a Surge
Zacks Investment Research · 3d ago
REGN vs. ILMN: Which Stock Is the Better Value Option?
Zacks Investment Research · 3d ago
BAYRY Q3 Earnings and Revenues Miss Estimates, Pharma Performs Well
Zacks Investment Research · 4d ago
Regeneron: 3 Key Takeaways for Long-Term Investors
The Motley Fool · Oct 31
REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
Zacks Investment Research · Oct 30
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Employees
15,410
30-Day Win Rate · REGN
15 days
9 days
Last 24 sessions
How to practice trading REGN
- 1
Use the REGN buy panel above
Set a quantity and hit Buy at the real market price — right here, nothing to download.
- 2
Trade with €1,000,000 virtual cash
You get a million in virtual money instantly to invest, risk-free.
- 3
Create a free account to save it
Sign up in seconds to keep your portfolio and track its performance.
- 4
Track and compete
Watch your portfolio grow and climb the global leaderboard — or start a private league.
- 5
Prefer mobile? Get the iOS app
Invest is also free on the App Store, synced with your web account.
Top REGN traders on Invest
Full leaderboardFrequently asked questions
Is REGN a good stock to buy right now?
As of November 8, 2026, Invest's signal rates REGN a Buy, based on its price trend, valuation, and fundamentals, with the stock up 40% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading REGN risk-free first.
What is Regeneron Pharmaceuticals Inc's (REGN) market cap?
Regeneron Pharmaceuticals Inc has a market capitalization of approximately $93.6B.
How has REGN stock performed?
REGN is up 40% over the past year and up 27% over six months. Its 52-week range runs roughly from $591.52 to $991.73. Past performance doesn't predict future results.
How can I practice trading REGN for free?
On Invest you get €1,000,000 in virtual cash and can buy REGN at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.
More stocks to practice
Designs the iPhone, Mac, and a huge services ecosystem.
Windows, Office, Azure cloud, and enterprise software.
The leading designer of AI and gaming GPUs.
E-commerce giant and the largest cloud provider (AWS).
Google Search, YouTube, Android, and cloud.
Facebook, Instagram, WhatsApp, and the metaverse.
Compare REGN with peers